Ontology highlight
ABSTRACT: Medulloblastomas (MBs) are malignant pediatric brain tumors that are molecularly and clinically very heterogenous. The application of omics technologies - mainly studying nucleic acids - has significantly improved MB classification and stratification, but treatment options are still unsatisfactory. The proteome and their N-glycans reflect the phenotype of a tumor in a more direct way and thus hold the potential to discover clinically relevant phenotypes and targetable pathways. We compiled a harmonized proteome dataset of 167 MBs and integrated findings with DNA methylome and N-glycome data. Six proteome MB subtypes emerged, that could be assigned to two main molecular programs: transcription/translation (pSHHt, pWNT and pGroup3myc), and synapses/immunological processes (pSHHs, pGroup3 and pGroup4). Multiomic analysis revealed different conservation levels of proteome features across MB subtypes at the DNA methylome level. Aggressive pGroup3myc MBs and favourable pWNT MBs were most similar in cluster hierarchies concerning overall proteome patterns but showed different protein abundances of the vincristine resistance-associated multiprotein complex TriC/CCT and of N-glycan turnover-associated factors. The N-glycome reflected proteome subtypes and complex-bisecting N-glycans characterized pGroup3myc tumors. Our results shed light on new targetable alterations in MB and set a foundation for potential immunotherapies targeting glycan structures. Metabolite profiling is reported in the current study MTBLS9830. Amino acid profiling is reported in MTBLS9836.
INSTRUMENT(S): Liquid Chromatography MS - negative
SUBMITTER: Antonia Gocke
PROVIDER: MTBLS9830 | MetaboLights | 2024-05-30
REPOSITORIES: MetaboLights
Action | DRS | |||
---|---|---|---|---|
MTBLS9830 | Other | |||
FILES | Other | |||
a_MTBLS9830_LC-MS_negative__metabolite_profiling.txt | Txt | |||
i_Investigation.txt | Txt | |||
m_MTBLS9830_LC-MS_negative__metabolite_profiling_v2_maf.tsv | Tabular |
Items per page: 5 1 - 5 of 6 |